Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma

被引：0

作者：

Astrid Lièvre

Bérèngere Ouine

Jim Canet

Aurélie Cartier

Yael Amar

Wulfran Cacheux

Odette Mariani

Rosine Guimbaud

Janick Selves

Thierry Lecomte

Serge Guyetant

Ivan Bieche

Frédérique Berger

Leanne de Koning

机构：

[1] Service des maladies de l’appareil digestif,Department of Translational Research

[2] CHU Pontchaillou,Department of Medical Oncology

[3] Université Rennes 1,Department of Genetics

[4] Faculté de médecine,Department of Pathology

[5] Inserm ER440-Oncogenesis,undefined

[6] Stress and Signaling,undefined

[7] Rue Bataille Flandres-Dunkerque,undefined

[8] Institut Curie,undefined

[9] PSL Research University,undefined

[10] Institut Curie,undefined

[11] PSL Research University,undefined

[12] Unit of Biostatistics,undefined

[13] Institut Curie,undefined

[14] René Huguenin Hospital,undefined

[15] Institut Curie,undefined

[16] Unit of Pharmacogenomics,undefined

[17] Institut Curie,undefined

[18] PSL Research University,undefined

[19] Biological Resource Center,undefined

[20] Centre de Recherche en Cancérologie de Toulouse,undefined

[21] Unité Mixte de Recherche,undefined

[22] Service d’oncologie médicale,undefined

[23] Centre Hospitalier Universitaire de Toulouse,undefined

[24] Toulouse 31059,undefined

[25] France,undefined

[26] Centre Hospitalier Universitaire de Toulouse,undefined

[27] Hôpital Trousseau—CHRU de TOURS,undefined

[28] Service d'Hépato-Gastro-Entérologie,undefined

[29] UMR CNRS 7292 (GICC),undefined

[30] Université François Rabelais,undefined

[31] Hôpital Trousseau—CHRU de TOURS,undefined

[32] Service d'Anatomie et Cytologie Pathologiques—Tumorothèque,undefined

[33] Institut Curie,undefined

[34] PSL Research University,undefined

[35] INSERM U900,undefined

来源：

British Journal of Cancer | 2017年 / 117卷

关键词：

colorectal cancer; resistance; EGFR; biomarkers; cell signalling; RPPA; PI3K;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1819 / 1827

页数：8

共 468 条

[1]

Amado RG(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634

[2]

Wolf M(2014)ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics Cancer Cell 25 282-303

[3]

Peeters M(2014)A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity Oncogene 27 588-495

[4]

Van Cutsem E(2011)Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer Br J Cancer 104 488-1261

[5]

Siena S(2010)Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 1254-523

[6]

Freeman DJ(2011)A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discov 1 508-267

[7]

Juan T(2015)The genomic landscape of response to EGFR blockade in colorectal cancer Nature 526 263-671

[8]

Sikorski R(2009)Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663-762

[9]

Suggs S(2010)Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 753-2160

[10]

Radinsky R(2013)RAS mutations in colorectal cancer N Engl J Med 369 2159-685

← 1 2 3 4 5 6 7 8 9 10 →